C024 - Updates in Hair Disorders

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

• Use up to date and evidence based information to assess, treat, and counsel patients with hair disorders.
• Discuss basic follicular biology and pathophysiology of common hair diseases

Description

This session will present new and noteworthy findings and approaches in the world of hair disorders. Cutting edge research in androgenetic alopecia, alopecia areata, cicatricial alopecia is leading to a better understanding of the pathogenesis of these disorders and promises new therapeutic options for our patients. Treatment of severe forms of these disease will be highlighted.

Disclosures

• Brinster, Nooshin Ketabchi, MD: Elsevier Inc. – O(IP);
• Lenzy, Yolanda M., MD: no financial relationships exist with commercial interests.
• Olsen, Elise A., MD: Aclaris Therapeutics, Inc. – C(H), I(Grants/Research Funding); Allergan, Inc – C(H); Allergan, Inc. – O(IP); Bioniz Therapeutics – C(H); Elorac, Inc. – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Helsinn Healthcare – O(H); Incyte Corporation – C(H); Lilly ICOS LLC – C(H); UpToDate, Inc – O(H);
• Salas, Sara L, MD: no financial relationships exist with commercial interests.
• Shapiro, Jerry, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Bioniz Therapeutics – A(Fees); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'Oréal France – C(H); RegenLab – I(Grants/Research Funding); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H);
• Sinclair, Rodney Daniel, MD: Aclaris Therapeutics Inc. – I(Fees); Amgen – I(Fees); Ascend Pharmaceuticals, Inc. – B(Fees); Bayer – Speaker/Faculty Education(H); Boehringer Ingelheim – I(Grants/Research Funding); Botaneco – I(Fees); Celgene Corporation – I(Fees); Coherus Biosciences – I(Fees); CSL – C(Fees); Cutanea Life Sciences – I(Fees); GlaxoSmithKline – I(Fees); inVentiv Health – I(Fees); Janssen Pharmaceuticals, Inc – O(Fees); Johnson & Johnson Pharmaceutical Research & Development – I(Fees); Leo Pharma Inc – A(Fees); Medimmune – I(Fees); Medpace – I(Fees); Merck & Co., Inc – I(Fees); Merck Serono – I(Fees); Novartis – I(Fees); Pfizer Inc. – I(Fees); PPD Inc. – I(Fees); Principia Biopharma Inc – I(Fees); Regeneron Pharmaceuticals, Inc. – I(Fees); Revian LTD. – I(Fees); Samson Clinical – F(IP); UCB – I(Fees);
• Tosti, Antonella, MD: Aclaris Therapeutics, Inc. – A(H); Anacor Pharmaceuticals, Inc. – A(H); DS Laboratories – C(Fees); Fotofinder – C(EQ); Incyte Corporation – C(H); Kurt Wolff GmbH & Co. KG – A(H); Kythera – A(H); Meiji Seika Pharma Co., Ltd – A(H); MSD – SP(H); Novartis – A(H); PharmaDerm – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Polichem SA – A(H); Procter & Gamble Company – A(H); Springer Science & Business Media – O(IP); Taylor & Francis – O(IP); topica – C(Fees); Valeant Pharmaceuticals International – C(Fees); Viamet Pharmaceuticals, Inc – A(H);
• Washenik, Ken, MD, PhD: Aclaris Therapeutics Inc. – C(H); Allergan, Inc – C(H); Cassiopea S.p.A. – C(H); Cicatricial Alopecia Research Foundation – B(NC); Follica – A(H), A(SO); Hair Foundation – B(NC); International Society of Hair Restoration Surgery – B(NC); Kerastem – A(H); North American Hair Research Society – B(NC); Theradome – O(NC);